Government Ban On 344 Drugs

Delhi High Court stayed on Thursday a government ban on 344 drugs that it deemed lacked therapeutic efficacy, after over six months of hearing more than 300 petitions filed by drugmakers against it.

The pharma sector is expected to report good growth for the fourth quarter of 2015-16 despite regulatory concerns raised by US Food and Drug Administration (FDA) and the recent ban on 344 fixed dose combinations imposed by the government, a report by Centrum Broking said.

Government on Thursday told Delhi High Court that the decision to ban 344 fixed dose combination (FDC) drugs was taken keeping in view "safety, efficacy and rationality" of these medicines.

In what could be the Maggi moment for the pharma majors, the Delhi High Court will today hear cases filed by various pharmaceutical companies against a ban imposed by the central government on 344 drug combinations.

The High Court will hear the case in a week. The ban on Pfizer's cough syrup was part of a wider notice issued by the government over the weekend prohibiting the sale and manufacture of 344 combination drugs blacklisted by a panel of experts.

The ban on Pfizer's cough syrup was part of a wider notice issued by the government over the weekend ordering prohibition of the sale and manufacture of 344 combination drugs that a panel of experts found posed a risk to humans.

Delhi High Court stayed on Thursday a government ban on 344 drugs that it deemed lacked therapeutic efficacy, after over six months of hearing more than 300 petitions filed by drugmakers against it.

The pharma sector is expected to report good growth for the fourth quarter of 2015-16 despite regulatory concerns raised by US Food and Drug Administration (FDA) and the recent ban on 344 fixed dose combinations imposed by the government, a report by Centrum Broking said.

Government on Thursday told Delhi High Court that the decision to ban 344 fixed dose combination (FDC) drugs was taken keeping in view "safety, efficacy and rationality" of these medicines.

In what could be the Maggi moment for the pharma majors, the Delhi High Court will today hear cases filed by various pharmaceutical companies against a ban imposed by the central government on 344 drug combinations.

The High Court will hear the case in a week. The ban on Pfizer's cough syrup was part of a wider notice issued by the government over the weekend prohibiting the sale and manufacture of 344 combination drugs blacklisted by a panel of experts.

The ban on Pfizer's cough syrup was part of a wider notice issued by the government over the weekend ordering prohibition of the sale and manufacture of 344 combination drugs that a panel of experts found posed a risk to humans.